The tuberculosis (TB) burden in the WHO European Region as a whole is decreasing, and is down 19% overall for 2015–2019, according to the latest WHO/European Centre for Disease Prevention and Control (ECDC) report Tuberculosis surveillance and monitoring in Europe 2021 (2019 data).
This annual meeting of National ECDC Correspondents and Observers National Focal Point (NFP) for Surveillance focused on the developments in technical cooperation over 2022.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-25 February 2017 and includes updates on Hepatitis A virus, Yellow fever and seasonal influenza.
The elimination of tuberculosis (TB) in Europe will require the management of latent tuberculosis infection (LTBI) in key populations. Management of LTBI requires the identification and adequate treatment of infected people. It is currently unknown how screening and treatment of key populations should be best organised to have the highest impact with the available resources.
In 2015, 34 651 cases of hepatitis C were reported from 28 EU/EEA Member States, a crude rate of 8.6 per 100 000 population. Of the cases reported, 1.0% were classified as acute, 12.7% as chronic, 69.5% as ‘unknown’ and 16.8% were not classified.
During the International Conference on (re-)emerging infectious diseases in Addis Ababa, ECDC Director Andrea Ammon presented ECDC's response activities, preparedness work and training activities.
This update was produced by ECDC after new information on the event background become available. The main conclusions and options for response remain unchanged from the version dated 19 October 2016.
This interim guidance outlines the possible strategies that countries may wish to adopt in the deployment of a pandemic-specific vaccine, considering the two objectives of vaccination: protecting those at greatest risk of severe disease and maintaining essential services.